Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CASIRIVIMAB\IMDEVIMAB vs CEFDINIR: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

CASIRIVIMAB\IMDEVIMAB vs CEFDINIR: Safety Overview

Metric CASIRIVIMAB\IMDEVIMAB CEFDINIR
Total FAERS Reports 4,248 1,627
Deaths Reported 137 35
Death Rate 3.2% 2.2%
Hospitalizations 1,351 262
Average Patient Age 54.3 yrs 37.8 yrs
% Female Patients 55.4% 65.6%
FDA Approval Date N/A Apr 6, 2007
Manufacturer N/A Sandoz Inc
Route N/A ORAL
Marketing Status N/A Discontinued